FIELD: medicine.
SUBSTANCE: group of inventions refers to a pharmaceutical composition containing a CNP variant peptide selected from a group consisting of Met-CNP-37, Pro-CNP-37, Gly-CNP 37 (M32N), Pro-Gly-CNP-37, Met-Gly-CNP-37 and Gly-CNP-37; and citric acid monohydrate, sodium citrate dihydrate, trehalose dihydrate, D-mannitol, L-methionine and polysorbate 80. Group of inventions also relates to a method of treating skeletal dysplasia in a subject, comprising a step of administering said composition to a subject; a method of increasing long bone growth in a subject, comprising the step of administering to said subject a composition; kit for treating skeletal dysplasia, increasing growth of long bones or for increasing growth rate, containing said composition in borosilicate glass vessel.
EFFECT: group of inventions provides stability and preservation of functional properties of peptides.
58 cl, 2 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF C-TYPE NATRIURETIC PEPTIDE VARIANTS FOR THE TREATMENT OF SKELETAL DYSPLASIA | 2016 |
|
RU2794515C2 |
| VERSIONS OF C-TYPE NATRIURETIC PEPTIDE | 2010 |
|
RU2573911C2 |
| POLYPEPTIDES THAT ARE SOLUBLE RECEPTORS OF FIBROBLAST GROWTH FACTOR 3 (sFGFR3), AND WAYS OF THEIR APPLICATION | 2017 |
|
RU2751483C2 |
| USE OF OPTIONS OF NATRIURETIC PEPTIDE OF TYPE C FOR TREATMENT OF OSTEOARTHRITIS | 2016 |
|
RU2759679C2 |
| CNP PRODRUGS | 2016 |
|
RU2824988C1 |
| LONG-ACTING POLYPEPTIDES AND METHODS OF THEIR PRODUCTION AND ADMINISTRATION | 2014 |
|
RU2798845C2 |
| LONG-ACTING POLYPEPTIDES AND METHODS OF THEIR PREPARATION AND ADMINISTRATION | 2014 |
|
RU2746943C2 |
| TREATMENT AND FUNCTIONAL CURE OF HIV-INFECTION WITH MONOCLONAL ANTIBODIES TO CD4 MEDIATING COMPETITIVE INHIBITION OF HIV ENTRY | 2014 |
|
RU2762315C2 |
| ANTIBODIES TO B7-H1 AND CTLA-4 FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER | 2015 |
|
RU2806210C2 |
| TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION WITH FIBROBLAST GROWTH FACTOR 3 (sFGFR3) SOLUBLE POLYPEPTIDES | 2018 |
|
RU2794170C2 |
